Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doriano Fabbro

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Gastroenterology|November 8, 2006
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivityEllen Weisberg, Renee D Wright, Jingrui Jiang, et al.
Blood|September 29, 2005
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effectsKaroline V Gleixner, Matthias Mayerhofer, Karl J Aichberger, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|July 12, 2002
A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase CAndres Virchis, Kanagasabai Ganeshaguru, Steve Hart, et al.
Journal of Medicinal Chemistry|October 26, 2018
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological DisordersDenise Rageot, Thomas Bohnacker, Anna Melone, et al.
Haematologica|November 21, 2007
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KITKaroline V Gleixner, Matthias Mayerhofer, Karoline Sonneck, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 10, 2015
Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substratePetranka Krumova, Lauran Reyniers, Marc Meyer, et al.
Cancer Research|July 17, 2004
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activityPeter Traxler, Peter R Allegrini, Ralf Brandt, et al.
Cancer Research|July 20, 2007
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cellsNagako Akeno-Stuart, Michelle Croyle, Jeffrey A Knauf, et al.
Cancer Cell|September 6, 2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathwaySumin Kang, Shaozhong Dong, Ting-Lei Gu, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Gastroenterology|November 8, 2006
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivityEllen Weisberg, Renee D Wright, Jingrui Jiang, et al.
Blood|September 29, 2005
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effectsKaroline V Gleixner, Matthias Mayerhofer, Karl J Aichberger, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|July 12, 2002
A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase CAndres Virchis, Kanagasabai Ganeshaguru, Steve Hart, et al.
Journal of Medicinal Chemistry|October 26, 2018
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological DisordersDenise Rageot, Thomas Bohnacker, Anna Melone, et al.
Haematologica|November 21, 2007
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KITKaroline V Gleixner, Matthias Mayerhofer, Karoline Sonneck, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 10, 2015
Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substratePetranka Krumova, Lauran Reyniers, Marc Meyer, et al.
Cancer Research|July 17, 2004
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activityPeter Traxler, Peter R Allegrini, Ralf Brandt, et al.
Cancer Research|July 20, 2007
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cellsNagako Akeno-Stuart, Michelle Croyle, Jeffrey A Knauf, et al.
Cancer Cell|September 6, 2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathwaySumin Kang, Shaozhong Dong, Ting-Lei Gu, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Pageof 13